DDInter1042 DDInter1881
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramelteon
Troglitazone {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Troglitazone may lead to a major life threatening interaction when taken with Mipomersen